INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family of transcription factors, a diverse group of proteins that mediate ligand-dependent transcriptional activation and repression. They modulate gene transcription in response to specific ligands by binding as heterodimers with the retinoid X receptor (RXR) to specific peroxisome proliferator-response element (PPREs) on target genes (reviewed in [1] ). So far, three distinct forms of PPARs have been described named PPARα, β (also called δ) and γ, each encoded by a different gene and showing a distinct tissue distribution [2] . In humans, PPARα is expressed in intestine, skeletal muscle, liver, kidney, adipose tissue and vascular endothelial cells [3, 4] . Several peroxisome proliferators have been shown to bind PPARα and to regulate transcriptional activity of target genes. These include the fibrate class of hypolipidemic drugs, non steroidal antiinflammatory drugs (NSAIDs), fatty acids and eicosanoids (reviewed in [5] ).
Interest in PPARs has increased dramatically since they were found to be involved in the regulation of processes as diverse as lipid and glucose metabolism, cell growth and inflammation.
Therefore, in addition to their well known effects in diabetes, pharmacological agents that target PPARs may have therapeutic applications in cancer and inflammatory diseases [6, 7] . In this sense, several reports have shown the potentially beneficial chemopreventive effect of PPARα ligands in colon carcinogenesis [8] [9] [10] [11] . Many of the anti-inflammatory and anti-neoplastic properties of PPAR ligands are due to their inhibitory effects on gene transcription [6, 12] .
PPARα agonists are involved in the transcriptional repression of a variety of inflammatory genes [13] [14] [15] . These effects seem to be mediated by the inhibition of various transcription factors such as nuclear factor (NF)-κB, activator protein-1 (AP-1) [16] and Sp-1 [17] .
On the other hand, a growing body of evidence has lighted the contribution COX-2 and VEGF genes in inflammation, tumor growth and angiogenesis (reviewed in [18, 19] ).
Cyclooxygenases, COX-1 and COX-2, catalyze the conversion of arachidonic acid (AA) to PGH 2 , the key step in the biosynthesis of prostanoids. COX-1 is constitutively expressed in most tissues, whereas COX-2 expression is induced by cytokines, mitogens, and tumor promoters in a discrete number of cell types (reviewed in [20] ). COX-2 is aberrantly overexpressed in many human cancers, most notably of colon origin [21] , being considered to play an essential role in cancer progression, especially in colon carcinoma. Multiple studies have revealed a role of selective COX-2 inhibitors in decreasing the risk of developing colon cancer and in suppressing 4 tumor formation and growth in animal models [18, 22] . Besides, accumulating evidence supports a key role of VEGF in cancer, contributing to tumor neovascularization and dissemination.
Increased expression of this factor has been found in most tumors and blockade of VEGF expression or activity ameliorate tumor growth in vivo (reviewed in [23, 24] ).
Here, we have tested the effect of two structurally different PPARα activators as the hypolipidemic drug WY-14,643 and the leukotriene D4 antagonist LY-171883 in the regulation of COX-2 and VEGF gene expression in the colon carcinoma cell line SW620. Our results show that PPARα activators specifically suppressed transcriptional induction of COX-2 and VEGF by phorbol esters. These drugs inhibited up-regulation of COX-2 and VEGF by inhibiting AP-1 mediated transcriptional activation through a negative cross-talk between PPARα and AP-1 transcription factors
EXPERIMENTAL

Reagents
Opti-MEM, RPMI, glutamine and antibiotics were from Invitrogen. Fetal bovine serum (FBS) was purchased from Euroclone. Phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 (Ion) were from Sigma (St. Louis, MO were from Sigma and Merck.
Cell Culture
The human colon carcinoma cell line SW620 was grown in RPMI medium supplemented with 10% fetal calf serum, 2 mM L-glutamine and antibiotics. The human colon carcinoma cell line Caco-2 was grown in MEM culture medium supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 2 mM L-glutamine, 0.1 mM non essential amino acids and antibiotics. The COS-7 cell line was cultured in standard conditions in DMEM culture medium. Cells were grown and maintained at 37ºC in a humidified atmosphere containing 5% CO 2 up to 70 % confluence and trypsinized with 0.25 % trypsin, 2 mM EDTA for experimental use. Cells were changed to medium with 0.5 % FBS prior to treatment with pharmacological reagents. No evidence of significant toxicity was observed at the doses used in any of our experiments as determined by the WST-1 cell viability assay.
Plasmid Constructs
The COX-2 promoter construct COX-2-LUC contains the -1796 to +104 region of the human COX-2 gene in pXP2LUC plasmid. The 431-κB-COX-2-LUC mutant was generated by site-directed mutagenesis using the oligonucleotide 5´-GACAGGAGAGTGGtacCTACCCCCTCTGCTCCC-3´ (nucleotides -236 to -204 of the human COX-2 gene containing the NF-κB site as described previously [25] . The VEGF-LUC plasmid contains the region -1910 to +379 of the human VEGF promoter [26] . The -73Col-LUC plasmid includes the AP-1 dependent region (73/+63bp) of the human collagenase promoter fused to the luciferase gene [27] . The NF-κB-Luc reporter plasmid contains a three tandem repeat of the NF-κB-binding motif of the H-2k gene upstream of the thymidine kinase minimal promoter [28] . The expression plasmid encoding PPARα was a generous gift of Dr. B Staels.
[13]. PPARγ expression vector and those containing the transactivation ligand binding domains of PPARα or PPARγ fused to the GAL4 DBD (pCMX-Gal-L-mPPARα) were provided by Dr. R. M. Evans [29] . The reporter plasmid PPRE-LUC containing three copies of the peroxisome-proliferator response element (PPRE) of the acyl-CoA oxidase (ACO) was a generous gift from Dr. B. 
Immunoblot Analysis
SW620 or Caco-2 cells were disrupted in ice-cold lysis buffer (50 mM Tris-HCl (pH 8),
10 mM EDTA, 50 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF). Solubilized extracts (30 µg) were separated by SDS-PAGE on 10% 
Electrophoretic Mobility-Shift Assays
Nuclear extracts were prepared from SW620 cells as described previously [31] . Protein concentration was determined by the Bradford assay (Bio-Rad). 5 µg of nuclear protein was incubated with 1µg of poly(dI-dC) DNA carrier in DNA-binding buffer (2% (w/v) polyvinyl ethanol, 2.5% (v/v) glycerol, 10 mM Tris, pH 8, 0.5 mM EDTA, 0.5 mM dithiothreitol) with 6mM MgCl 2 for 10 min. The DNA binding reactions was performed by adding 50,000 cpm of 32 P-labeled double-stranded AP-1 consensus oligonucleotide (5´-CGCTTGATGAGTCAGCCGGAA-3´) (Promega) and incubated at room temperature for 15 min. A 30-fold molar excess of unlabeled oligonucleotide was added before the addition of the probe for competition when indicated. DNA-protein complexes were resolved by electrophoresis on 4% nondenaturing polyacrylamide gels.
Cell Viability Assay
The viability of the cells was measured by the use of the tetrazolium salt WST-1 (Roche Molecular Biochemicals) as previously described [31] . SW620 cells were incubated for 3, 6 and 24 hours in the presence of increasing doses of PPARα ligands (10, 50 and 100 µM) and/or PMA + Ion and incubated with 10% WST-1 reagent. The formazan dye produced by metabolically active cells was quantified by spectrophotometrical measurement.
Statistical analysis
Data are expressed as mean ± SE and their statistical analysis was performed with Student´s t test. Ps< 0.05 were considered to be significant. All the experiments shown are either representative or the mean of triplicates of at least two independent ones performed in order to guarantee the reproducibility and the significance of the results. 
RESULTS
PPARα ligands LY
PPARα ligands inhibit transcriptional induction of VEGF and COX-2 promoters
We next analyzed whether the effects of the PPARα ligands LY-171883 and WY-14,643
on PMA -mediated induction of COX-2 and VEGF were taking place at the transcriptional level.
In agreement with data obtained with the mRNA and protein, PMA strongly induced the transcription driven by human COX-2 (pCOX-2 LUC) or VEGF (pVEGF-LUC) promoters in SW620 cells ( Figure 3A Transcriptional activation by c-Jun can be also modulated by the regulation of the activity of its intrinsic transactivation domain by serine phosphorylation [35] . As shown in Figure 6B have demonstrated that NSAIDs, agents inhibiting COX-2 -derived prostaglandin production, appear to be effective in cancer prevention [40] . Noticeably, some NSAIDs may act as PPARα and γ ligands suggesting that, in addition to inhibit prostaglandin production, they might also regulate gene expression as part of their anti-inflammatory and chemopreventive mechanisms [41] . PPARs are expressed in the intestine at various levels, playing an important role in the development of colon carcinomas [11, 42, 43] . Although PPARγ is the predominant isoform, PPARα is also expressed in the colon, being able to participate in the differentiation of malignant tumor cells [8, 44, 45] . Several reports point to PPARα ligands as potentially beneficial chemopreventive agents in colon carcinogenesis. Tanaka and cols have demonstrated that PPAR agonist including bezafibrate, a PPARα ligand are able to suppress chemically induced aberrant crypt foci formation in the rat colon [9, 11] . In addition, this PPARα agonist has been reported to suppress intestinal polyp formation in Apc-deficient mice [10] . Moreover, methylclofenapate, a drug displaying properties as a PPARα agonist is also able to reduce intestinal polyp size and number in APC min/+ mice [8] . Kohno et al. [9] have recently reported that both, the COX-2
inhibitor Nimesulide and PPAR ligands inhibit colitis-related colon carcinogenesis. These authors reported that bezafibrate, a PPARα agonist, significantly reduced the incidence of chemically- 
